Certain rheumatoid arthritis therapies could reduce cardiovascular disease risk in rheumatoid arthritis patients.
Rheumatoid arthritis (RA) therapies may reduce cardiovascular disease risk in RA patients, according to a research presentation by Dr. Joan Bathon, chief of the Division of Rheumatology at Columbia University College of Physicians and Surgeons, at the recent Congress of Clinical Rheumatology held in Destin, Florida.
In the presentation, “The effect of RA therapies on the outcome of cardiovascular disease, insulin resistance and other comorbidities,” Dr. Bathon noted that prospective and cross-sectional studies she conducted have looked at subclinical measures of atherosclerosis and CV events, and the incidence of systematic, vascular, and articular inflammation.
“We looked at epidemiological evidence of association of increased rates of cardiovascular (CV) disease in patients with rheumatoid arthritis (RA),” she said in a news release. “We wanted to find the effect of rheumatoid inflammation and RA treatments on modifying risk of CV disease, metabolic pathways, insulin resistance and other comorbidities.”
|Read Full Article: Rheumatoid Arthritis Treatments Can Lower Cardiovascular Disease Risk, Researcher Says | Rheumatoid Arthritis News|